MedPage Today on MSN
Endocrine Therapy Resistance in HR+/HER2- Breast Cancer: A Common Clinical Challenge
Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...
Researchers from The University of Texas MD Anderson Cancer Center have discovered a previously unknown mechanism that ...
Atrandi Biosciences will present its latest developments at the American Society of Human Genetics (ASHG) 2025 Annual Meeting ...
(Nanowerk Spotlight) Scientists manipulating living cells face a fundamental challenge: working with thousands of samples at the nanoliter scale – volumes measured in billionths of a liter. At this ...
Zero-trust security mirrors biology’s best defenses. By applying least privilege, businesses can scale, stay resilient and protect systems with clarity and control.
TipRanks on MSN
Regeneron’s Odronextamab Study Update: A Potential Game-Changer in B-Cell Malignancies
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals recently updated its clinical ...
BioLamina CEO Klaus Langhoff-Roos discusses the challenges of scaling stem cell production from lab plates to bioreactors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback